Categories

Above the Fold

POLICY: A Riposte to Physicians Who Post on THCBBy the Industry Veteran

The Industry Veteran joins us this afternoon in the latest in THCB’s series by guest posters, following up on excellent posts by veteran financial journalist  Maggie Mahar and orthopedic surgeon turned talk show host Eric Novack. The Veteran found Eric’s comments on the health care system inspiring — to put it mildly. They set him to thinking about the true role of physicians in the healthcare system and in society at large. Needless to say, as always on THCB, his words are his alone.     
    
   

On this sunny morning I thought I might take time away from more productive pursuits to answer some of the typically narrow minded and self-serving posts of the physicians who attend THCB in the same way that dogs raise their hind legs at convenient lampposts.  The object of my opening disdain is someone by the name of Dr. Eric Novack.  Alas, Maggie Mahar demolished his drivel in a more cordial manner.  Novack’s transparently phony views suggest an analogy to Samuel Johnson’s comment about a dog walking on its hind legs.  Physicians writing about politics, health care economics or social policy are similar to this canine trick in that it is almost never done well; the wonder is that it is done at all.

Other physicians seeking to foist their miscreant views on THCB usually content themselves with illogical or poorly informed letters that disagree with some of my posts.  I don’t wish to be too caustic in responding to their blatant ignorance.  After all, they spent years performing brute rote memorization and other, low cognitive tasks, so their distorted thinking is a product of their trained incapacity.  While it isn’t terribly useful to disparage plumbers for being poor cooks, the pipe cutters who consider themselves master chefs despite an inability to boil a potato do merit some contempt.

A few themes of disagreement and bewilderment emerge from the physicians’ posts.  One chap, for example, asks about the “de-skilling” reform that I urge upon medical practice.  I realize that memorizing bones and ways to add carbonyls to benzene rings doesn’t leave much time for understanding history, so I’ll try to provide a remedial lesson.

In the late 19th and early 20th centuries, the pace and substantive nature of industrial production was largely directed by skilled craftsmen on the production floor.  This situation stymied the interests of managers who considered matters of volume, configuration, quality and cost as matters for their control. Their solution, as implemented by Henry Ford and others, consisted of the assembly line for which workers with far less skill could be inserted or removed as interchangeable parts.  Labor historians have actually documented many periods of de-skilling throughout the industrial revolution.

As applied to medical practice, the process consists of pushing the scope of practice, discretion and competence down the food chain.  Primary care practitioners should do a fair amount of the things that only specialists do at present.  Nurse practitioners should assume responsibility for many primary care functions, PAs should get other responsibilities, and so on.  Other health care professionals such as pharmacists and nurses should also assume more physician responsibilities.  Of course, physicians for years have berated such “assembly line medicine,” “therapeutic triads” and other labels for the process, despite the fact that studies have shown it produces better outcomes and lower costs.

Other affirmers of the Hippocratic oath who seek to recoup the costs of their medical education from their first four patients find fault with my call to feminize medicine and increase the number of foreign medical graduates.  They claim that even now, 50% of practitioners are women and most hospital physicians are FMGs.  Their figures are possibly correct, but their claim is equivalent to saying that Hispanics, blacks, Asians, poor whites and the aged infirm run the US because there are so many of them.  I merely ask these disingenuous posters to examine the ranks of service chiefs at major teaching hospitals, the senior faculty at top medical schools and the key opinion leaders who speak on behalf of the Big Pharma companies at medical conventions.  Only small percentages of these big, swinging schwanzes are women or FMGs.

A few years ago I systematically examined the reasons for this paucity of women in the medical profession’s key positions.  Basically, the motivations and the personality profiles of influential physicians approximate those of senior executives at the largest 1000 companies.  The desire for wealth, status, power, ego and other forms of self-aggrandizement predominate.  For some of the same reasons that the numbers and influence of women in the corporate boardrooms remain small, their sway in the medical profession is also puny.  In most cases, women are just the working stiffs and peons of the profession.  That stratification of medicine won’t do.  I’m talking about making medicine a feminine profession in the same way as elementary school teaching, nursing and public librarianship.  That will incentivize you egocentric males and the small number of female-impersonating women in the profession to ply your greedy ways in business without the special dispensations that society grants to physicians.

Finally, I don’t know whether I’m amused or nauseated by the posts from physicians who seek to justify their claims to unconscionable incomes by citing the many years they spent in school and the related costs.  Along the same line, a cardiologist at the American College of Cardiology meeting told me that the country should guarantee cardiologists a starting salary of $250,000, at a minimum, because they had to forego the enjoyments of their years between the ages of 20 and 30.

Well, according to the logic of THCB’s greedhead physicians, veterinarians sure get a raw deal because they spend quite a few years in training and receive only a fraction of MDs’ salaries.  Of course PhDs really take it up the sphincter, with all the years they spend in graduate school, a series of post-doc positions in indentured servitude, and then some really chancy prospects of even getting a job.

The lesson here is not like memorizing the steps of the Krebs cycle or the twelve cranial nerves, so I’ll take it slowly for sawbones readers.  No mnemonic devices or acronyms are required. 

One’s income in a market economy is not based upon years of schooling, contribution to society (whatever that means), or any other assessment of intrinsic worth.  Instead, labor is a product that seeks its economic rent in a competitive market and, like any other product, it captures whatever willing buyers will pay for it.

Of course, if one’s profession obtains a legal monopoly through state licensure and then chokes off the labor supply, buyers in the market will have to pay more for that particular labor.

Alas, the day proceeds and I can waste no more of it instructing arrogant, ignoramus physicians.  I charge by the hour and since I don’t make the return on equity of a Big Pharma company, I see no need to coddle your swinish asses.

As a parting shot, I see that Dr. Novack identifies himself as an orthopedic surgeon.  This information reminds me of an old axiom that made the rounds in the pharmaceutical industry several years ago.  Before the prevalence of Ken and Barbie reps, the ranks were smaller and populated by pharmacists and others with graduate degrees in the health sciences.  Many of these sales people used to complain about the fact that they needed to dumb down the detail presentations so drastically for some specialties.  That’s when one wag passed around the story about the procedure used by residency programs for selecting new people.  According to his apocryphal tale, teaching hospitals would take the bottom 10% of med school graduating classes and if people in this tier could bench press 200 pounds or more, they were taken into orthopedic programs.  Those unable to push the bar to arm’s length went into OB/GYN.  I suspect Dr. Novack had two nurturing nurses spotting for him and they raised the bar from both ends.  —  Industry Veteran

POLICY: Two Scenarios … By Eric Novack

Here is a quick hit for the day. We have read about Medicare (actually CMS, but it sounds better to give Medicare its own personality) publishing payments for 30 procedures. I encourage you check out cms.gov and try to actually understand the Excel file that you get for your efforts.

Only government could call that ‘disclosure.’

Private insurers are also getting into the mix. We have all heard about Aetna publishing the range of reimbursement
  for contracted physicians. Many other companies are announcing that they will
  follow suit. These news reports always include the comment that physicians and
  hospitals do not want this published. I disagree.

Two scenarios can emerge from this, once all insurers publish reimbursement 
rates (and they are not mutually exclusive).

As an orthopedic surgeon, I will use an orthopedic example. If insurer X reports
  publicly that the range of reimbursement for treating a broken wrist ranges from $500 – $750, I will obviously immediately go and check to see where I am
  on that scale. If I am at the low end, I will definitely not sign a new contract
  with that insurer for less than what my colleagues are getting for the same
  work. I will not be alone.

Scenario two is more intriguing. Once all insurers publish their fee schedules, doctors no longer need to participate in insurance plans. All I need to do is set my rates comparably- and reasonably- and drop all the insurance plans. And I can eliminate much of my billings/collection staff. I can also now account
  for the actual work it takes to do different things—and perhaps accept lower
  payment for some things, while charging more for much more complex work. (The example I use is joint replacement: a re-do [revision] joint replacement also pays about 20% more than a first time [primary] joint replacement, even though it can take 4x the work, with increased liability.)

The disclosure would have the absolute opposite effect on insurers than they intended. Although I suspect the smart folks at Aetna, UnitedHealthcare, Healthnet, and others have considered this already, and it is why they are so reluctant to actually make public this information.

POLICY: If You Can’t Beat Them, Beat Them Back By Thomas Leith

The Wall Street Journal reported in a June 13th article,
  Page D1
that several major insurers (Aetna, Cigna, Humana, UnitedHealth)
  as well as Medicare are disclosing the prices they have negotiated with doctors
  and hospitals for a number of common procedures. Some are beginning to include
  quality indicators with the pricing information. This is an apparently-growing
  trend that may spell doom for companies like HealthGrades,
  but this wasn’t noted in the article. One interesting thing: apparently at least
  a few insured people have used the system, even though they’ll be well past
  the deductible. Maybe some few will note a link between the premiums they pay  and the Medical Loss Ratio their insurer experiences. On the other hand, the
  article notes that in the absence of any other quality indicator, people may
  think that more expensive implies higher quality and choose the
  high-cost provider.

The insurer’s tools are restricted to their own plan members: this means if
  you’re covered through Cigna you can’t tell what out-of-pocket costs might be
  for somebody covered by (say) United. The article goes on to detail several
  of the limitations inherent in these disclosures, well-known to readers of The
  Healthcare Blog. Tools like these might actually be useful to those with HDHP
  coverage, or the uninsured.

But there’s more. The article says states are beginning to mandate that hospitals
  disclose their charges. Charges amount to the "list price" that almost
  nobody pays, so this isn’t very helpful to prospective patients. The list includes
  South Dakota, Minnesota, and Florida. I wonder who got the states to mandate
  that instead of something useful. Some state hospital associations are evidently
  taking proactive measures, and have created their own websites to disclose hospital
  charges before being told they must. But why would they do this?

Look at this from the New Hampshire Hospital
  Association PricePoint system
:

How much do government programs pay compared to other payment
sources?
In many cases, Medicare & Medicaid reimburse hospitals at rates that do not
cover the costs they incur to provide care. Payments from privately insured
patients generally subsidize the shortfalls created by Medicare and Medicaid
and therefore represent a “hidden tax” on individuals and families not
covered by government programs.

Where have we heard this before?

When you ask for prices, you get median and mean charges with no promise that
  your bill will bear any resemblance to either figure, and this editorial.
  Apparently, they expect they’ll be forced to disclose someday, and this way
  they can control the content of the disclosure. If the legislature gets involved
  the hospitals might not be allowed to put their own "spin" on things. This actually
  is brilliant strategy. They’re not disclosing very much, but they can claim
  they’re being as transparent as they can be, given the vagaries of medical treatment.
  They can lobby commercially-insured patients to lobby congress to increase Medicare
  reimbursements with an implication that the amount they pay in "hidden taxes"
  will go down. But of course it won’t. They do not mention that there are many
  cases for which Medicare & Medicaid reimburse hospitals at rates that exceed
  the costs they incur to provide care. Imagine! Finally, they offer no assurances
  that the costs they incur to provide care are reasonable.

POLICY: The Three Percent Myth By Eric Novack M.D.

As the premier health policy blog on the net, I am honored that Matthew has asked me to occasionally guest post here. I also am regularly impressed with
  the level of thought and knowledge of so many posters of comments.
  Every once in a while, I think it is important to review, what I would believe
  so basic myths about our healthcare system. One of the greatest myths is the
  3% overhead myth for medicare. (This is often also cited as the 2% overhead
  myth.)
  Argument one in favor of the ‘medicare for all’ expansion of government
  regulated healthcare is the disparity in overhead between Medicare and private
  insurance plans. The Medicare overhead number is stated as 2% or 3%, depending
  upon where you read it. The overhead for private insurers is stated as 15%-25%.
  The disparity is used to explain the statement that, “if we just take the
  amount spent on wasted overhead and apply it to medicare-for-all, we could easily
  pay for everyone to be covered”. Where does that math come from? Here’s
  the brief skinny:
  $2 trillion in healthcare. 50% from private sector= $1trillion. Reduce overhead
  by 15-20%= $150- $200 billion available.
  Oh, if it was so simple.
  Let’s attack the 3% myth.

Proponents say overhead should be calculated as: admin costs/ payout for services.
  However, medicare recipients use much more care, on average, than younger groups.
  So, for example (made up numbers), medicare recipients might use $5000 per year,
  while commercially insured people might use $3000 per year. If both groups consisted
  of 10,000 people, it would take the same amount of oversight, management, etc.,
  yet the perceived overhead to take care of the younger group would be much higher;
  or put the other way, medicare overhead would be much lower.Solution: calculate overhead on a ‘per enrollee’ scale. This alone
  accounts for 50% of the discrepancy in overhead between medicare and private
  payers. If you do not believe me, just check with the Kaiser Foundation research
  saying the same thing.
  Proponents focus on the low administrative costs, on the one hand, while denouncing
  the amount of fraud by hospitals, providers. This perhaps is because medicare  does not spend enough on administrative oversight of the program. This happens to be exactly what the GAO and the National Academy of Social Insurance has  said within the past 6 years. So, if medicare spent more on administration,
  the discrepancy would be decreased even further.
  Proponents fail to account that for every regulation, costs are incurred by
  providers to comply. The 100,000 plus pages of medicare regulations function
  as an unfunded mandate on providers. Currently, the coding is based on ICD-9,
  which has over 24,000 codes. ICD-10, slated to go into effect within the next
  2 years has over 207,000!!!! And does upgrading for the change count toward medicare overhead? Of course not.
  Proponents say that private insurance company rules would create as much hassle
  for providers. Perhaps, but we will never know since private insurance rules
  are based off of the medicare guidelines.
  Thus, the ‘medicare 3% myth’, is, in reality, just that: a myth.

But like most myths, true believers will never pay attention to facts.

PHARMA: Can There Be Too Many Cures for Cancer? by Maggie Mahar

Last week, an upbeat story
  in the New York Times
described how big pharmaceutical companies have discovered
  cancer. A few years ago, the article points out, companies like Pfizer, Glaxo
  and Wyeth had relatively little interest in what they saw as a "niche market."

While a great many people die of cancer, the disease takes so many different
  forms that each market is relatively small. Big Pharma generally would rather
  focus its research on diseases with a broad base-allergy medications, for example,
  are a big favorite (even if, according to the National
  Institute for Health Care Management
, most people taking allergy medications
  don’t actually suffer from allergies.)

Drugmakers also prefer drugs that customers can be counted on to take for many
  years. (There is a saying in the pharmaceutical industry: "A pill that
  cures is good. A pill that you take every day is better.") Cancer patients
  tend to "die within months," the Times pointed out, curtailing profits.

But recently, big drug-makers have begun to recognize that cancer drugs can
  be profitable-if the price is high enough:

". . . companies have discovered that some patients will tolerate prices
  of tens of thousands of dollars a year, " the Times observed, "making
  drugs for even rare cancers into big moneymakers. Gleevec, which is used primarily
  for two obscure cancers – chronic myelogenous leukemia and gastrointestinal
  stromal tumor – had sales last year of $2.2 billion."

The race to get on the cancer bandwagon could lead to a flood of "me too"
  drugs that duplicate each other, the article acknowledged. But from the standpoint
  of the patients there [are] never too many, cancer drugs, the article asserted,
  quoting Dr. Robert J. Motzer, a kidney cancer specialist at Memorial Sloan-Kettering
  Cancer Center in New York City.  After all, the more drugs there are in the
  pipeline, the better chance a patient has of finding one, or a combination,
  that will work for them. Besides "competition could . . . bring down prices,"
  the Times suggested.

Really? If so, that would be a first.

When it comes to healthcare, competition almost never leads to lower prices.
  In most markets, comparison shoppers reward quality at a lower price. But when
  you’re dying of cancer, you’re probably not hunting for a bargain-even if you’re
  paying 20% of the cost out of your own pocket.

More importantly, even if you wanted to compare cost and quality, how would
  you go about doing it? As anyone who has ever been seriously ill knows, the
  more you learn about the pros and cons of various treatments, the less certain
  you are likely to be as to which might be the best for you.

Ambiguity haunts medical care. In my newest book, (Money-Driven
  Medicine: The Real Reason Health Care Costs So Much
Harper/Collins, May
  2006 )," I quote Dr. Atul Gawande, who describes "uncertainty"
  as "the core predicament of medicine . . . the thing that makes being a
  patient so wrenching, being a doctor so difficult and being part of a society
  that pays the bills so wrenching."

A Boston surgeon and author of Complications: A Surgeon’s Notes On An Imperfect
  Science, Gawande is quick to admit that even the physician is often not at all
  sure as to the "best" treatment for a given condition. Little wonder
  that patients are not able to bring down prices by shrewdly picking the product
  that offers the best value.

As for the idea that when there are more drugs in the marketplace, patients
  stand a better chance of finding one that works, some physicians warn that too
  many new drugs only adds to the confusion in a marketplace where free market
  competition has turned into a free-for-all.

According to the Pharmaceutical Research and Manufacturers Association, some
  400 cancer drugs from 178 companies are now in clinical trials-and many oncologists
  complain that this is more cures than they can hope to keep track of.

A sign of the times: in 2004 the
  Times reported
that one session of the American Society of Clinical Oncology’s
  conference was titled "Therapy of Metastatic Colorectcal Cancer: What Do
  We Do with So Many Options?"

As each drug company races to fill its own pipeline, a fragmented industry
  spawns a dizzying array of half-way cures. Too many drugs shrink tumors-but
  don’t bring any mortality benefit. Meanwhile, too much competition and too little
  collaboration makes it difficult for oncologists to sort out which drugs are
  most effective alone, which should be used together-and in what sequence.

When I was writing Money-Driven Medicine Dr. Genie Kleinerman, chief of pediatrics
  at Houston’s M. D. Anderson Cancer Center, recalled how two companies refused
  to work together to help her prove that two of their drugs might do a better
  job of targeting malignant cells of osteosarcoma ( a bone cancer that occurs
  in children), if they were used in combination. In the lab, Kleinerman had shown
  that you could mix the two agents. Now, she needed the company to do clinical
  trials in order to win approval from the FDA.

"But the lawyers for the two companies couldn’t come up with an agreement
  on who would own the rights to the combination and who would pay for what,"
  Kleinerman recalled, still frustrated. "Today it would be the same situation
  -or probably worse. The pharmaceutical industry has become so protective of
  who owns the intellectual property. You probably couldn’t even get them to sit
  down at the same table."

Instead, companies pursuing parallel research squander millions producing tumor-shrinking
  drugs that, too often, offer "no
  improved survival, no better quality of life, no added safety
" according
  to one study in the British Medical Journal–though they almost always cost
  more.

And as the pharmaceutical industry’s big guns elbow their way into the cancer
  marketplace, peddling pills that cost tens of thousands for a course of treatment,
  they are gobbling up much-needed health care dollars. Paying for these drugs
  is straining the system. Two years ago, Bains & Company, a management consulting
  firm estimated
  that paying for all of the drugs in development would require $60 billion a
  year-up from $10 billion at the time.

"Who’s going to pay for that? It’s just going to become unaffordable,"
  said Elgar Peerschke, head of the North American health care practice at Bain.

Oncologists like Genie Kleinerman believe that if government gave drugmakers
  incentives to pool their research, they might be able to develop fewer, more
  effective and more affordable remedies at a lower cost. But that’s not how free
  market competition normally works-at least not according to the conventional
  wisdom of a market-driven health care system.

TECH: If he beeps, he’s clean Bob By John Irvine

“It’s really no different than a tamperproof passport you can carry all
the time,” Applied Digital CEO Scott Silverman, attempting to explain
why  his company’s proposal to use surgically
implanted RFID microchips to help keep tabs on immigrants is really not as
frightening as it sounds.  Silverman says Applied Digital subsidiary VeriChip wants to work
with the Department of Homeland Security to develop a guest worker program
using the technology. 

The VeriChip was approved by the Food and Drug
Administration for human use in 2002 but has not seen widespread usage in the
healthcare industry.  By way of contrast, the company claims the VeriChip has been implanted in about 30 million animals.

In an interview on Fox News several weeks ago, Silverman said
several congressional leaders have expressed interest in the idea of using the
technology for border control.

FOOTNOTED: It turns out that the Department of Homeland
Security may not be all that keen on the idea, anyway. A DHS sub-committee
released a report Wednesday which concludes that using RFID to track people is
probably not a good idea in the first place. The report, titled “The Use of
RFID for Human Identification
” by the Emerging Applications and Techology
Subcommittee, warns that potential privacy problems make the technology something the government should avoid for now. That conclusion
drew protests from the Information Technology Association of America (ITAA) ,
an industry trade group. While conceding
that privacy issues exist, a spokesman for the group blamed the negative review
on “insufficient industry expertise” on the panel…

Amazing the things you learn if you read magazines
with exciting titles like Government Technology. I’m hooked.

 

BLOGS: Medpundit quits

Damn–I never posted this when it happened last month! But I still mean it

—————

Medpundit stopped blogging last week.

Sydney drove me mad. We fought about ethics, politics and everything. But she inspired some of my best thinking.

She was (is) the doyen of medical blogging, and even when life got crazy she was the one doctor blogger I’d go back through mounds of posts to read.

She was the best. I genuinely think I read every post she wrote in the last three years. And I will miss her. Thanks, Syd.

CONSUMERS/HEALTH PLANS/HOSPITALS/TECH: Consumer comparison tools, not exactly wowing the world as yet

There’s a new report from CHCF, written by Katy Hendrickson at Forrester, it’s called  (pdf) Health Care Cost Comparison Tools: A market under construction. I’ve read it and it does suggest that something is slowly happening in the Submio/Health Grades world, but that it’s mostly about a few plans trying to steer consumers around based on quality….we are a long, long way from price transparency. Stll def worth a read if you’re all interested in consumerism, transparency or health care cost and quality. And apparently some of you are

There’s also a companion report out called Consumers in Health Care: Creating Decision-Support Tools That Work . I haven’t read that one yet. Comments please from anyone who does.

 

TECH: Conflict-of-interest! This is the best Modern Healthcare could do?

I greeted with glee an email from Modern Healthcare suggesting that there was some seedy goings on in the RHIO world. That article is called Conflict-of-interest questions arise over RHIOs. I was looking forward to the expose of fraud, graft and corruption. Frankly the article is pathetic, and an embarrassing attack on totally the wrong targets.

Essentially the article says that Molly Coye was tangentially involved in the steering of consulting work from the Cal RHIO which she basically started out of HealthTech, which she did start, to a consulting company called Health Alliant of which she was an unpaid Board Chair/Adviser. The article does note that Molly never got paid anything by Health Alliant and recused herself from the negotiations between Cal RHIO and Health Alliant. Meanwhile Blackford Middleton is also on the board of Health Alliant, as is Scott Wallace and apparently they at least approve and are damned by association.

Full disclosure; I know Molly and Blackford quite well, and am in general fans of theirs, so take what I say in that context. But frankly this article is clutching at straws.

Yes, Molly is influential in the whole RHIO movement. She put together the energy with David Brailer to start the whole national health IT initiative, and you can argue that much of the concept of small Federal money to kick-start the private sector came from her 2003 Health Affairs paper. Yes, Health Tech was funded primarily by big providers, and Molly used her contacts and influence to get them to pay to fund it—but I might modestly suggest that if they provided nothing in return, HealthTech’s membership would not have come back for year 2. Yet several years later they’re still there. Yes, given that HealthTech exists it was a natural venue for RHIO discussions in California. Yes, HealthTech (and CalRHIO, and, on a sadly much more modest scale, I) receive money from the California Health Care Foundation, but that’s to support work that is important to CHCF’s charter. And the article managed to miss the juiciest ridiculousity of all in that CHCF’s President is Molly’s ex-husband! Surely they could have made some hay there!

Health Alliant, which is largely run by Jeff Rose who’s been in the health IT game for a while, is making a little business out of helping fledgling RHIOs with strategic planning. But it is a little business, at most $4m this year—and given the low margins on that type of work I bet their profit is puny compared to just the overspend on expenses at King/Drew in Los Angeles, or what Deloitte billed at UC Davis. And it’s nothing compared to the mega-millions Blues of Tennessee and Blues of Florida spent  in the 1990s with Andersen Consulting developing software that never worked.

And most importantly, Molly bent over backwards to get out of the appearance of conflict of interest. I’m sure if she was raking it in somehow, we’d all be invited to spend time on her yacht.

Many among us may have doubts as to whether RHIOs will succeed, and whether this is all a waste of Foundation and taxpayer money. But that’s the way progress (such as it is) in American health care IT is made. The goals of the the RHIO movement are extremely laudable. That it exists at all is in no small part due to Molly (and Blackford and Scott Wallace). There were I assure you plenty of things they could have been doing in the last few years to get much richer if they’d chosen. But instead they spent their time in getting us some of the way towards those goals. How does that justify running a long story about a non-existent conflict of interest that made them no money (and probably had a negative opportunity cost)?

If they want to dig into Molly, perhaps they should look into her appointment to the Board of Aetna. Although one only needed to look at their 10K to find out about that. Sadly for her she doesn’t appear yet to have the $400K in Aetna stock that the Directors need to own (and persumably not sell when they’re still directors) according to Aetna’s by-laws. They gave her a bunch of options for being on the board. I’m not exactly sure from my reading of the document whether it was a gift rather than she had to buy in. Perhaps Jack Rowe can lend her some cash if she’s short.

But even that seems very minor compared to just some of the Board appointments in health care. Don’t you think she could have got herself on the board of any and every health IT company in the nation if she’d really wanted to cash in?

There are plenty of potential conflicts of interest with board appointments in health care. Roy Poses doesn’t have Modern Healthcare’s resources, but  he manages to snare one or more from time to time including having a go at some clear board gadlfy’s like Uwe Reinhardt.

As for real malfeasance in health care? It’s just hard to imagine that Modern Healthcare couldn’t find somewhere better to look.

assetto corsa mods